Business Description
Estrella Immunopharma Inc
NAICS : 541714
SIC : 2834
ISIN : US2975841048
Description
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.2 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -134.3 | |||||
| 3-Year EPS without NRI Growth Rate | -134.3 | |||||
| 3-Year FCF Growth Rate | -214.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 82.84 | |||||
| 9-Day RSI | 72.22 | |||||
| 14-Day RSI | 63.63 | |||||
| 6-1 Month Momentum % | -9.27 | |||||
| 12-1 Month Momentum % | -36.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.75 | |||||
| Quick Ratio | 0.75 | |||||
| Cash Ratio | 0.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1 | |||||
| Shareholder Yield % | 0.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -135.13 | |||||
| ROA % | -82.24 | |||||
| ROIC % | -776.6 | |||||
| ROC (Joel Greenblatt) % | -524.2 | |||||
| ROCE % | -135.1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 48.1 | |||||
| Price-to-Tangible-Book | 52 | |||||
| EV-to-EBIT | -1.67 | |||||
| EV-to-EBITDA | -1.67 | |||||
| EV-to-FCF | -0.82 | |||||
| Earnings Yield (Greenblatt) % | -59.88 | |||||
| FCF Yield % | -49.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ESLA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Estrella Immunopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.26 | ||
| Beta | 0 | ||
| Volatility % | 79.08 | ||
| 14-Day RSI | 63.63 | ||
| 14-Day ATR ($) | 0.108118 | ||
| 20-Day SMA ($) | 0.856475 | ||
| 12-1 Month Momentum % | -36.62 | ||
| 52-Week Range ($) | 0.63 - 3.23 | ||
| Shares Outstanding (Mil) | 36.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Estrella Immunopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Estrella Immunopharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Estrella Immunopharma Inc Frequently Asked Questions
What is Estrella Immunopharma Inc(ESLA)'s stock price today?
The current price of ESLA is $1.04. The 52 week high of ESLA is $3.23 and 52 week low is $0.63.
When is next earnings date of Estrella Immunopharma Inc(ESLA)?
The next earnings date of Estrella Immunopharma Inc(ESLA) is 2025-02-14 Est..
Does Estrella Immunopharma Inc(ESLA) pay dividends? If so, how much?
Estrella Immunopharma Inc(ESLA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers